Carregant...
The safety of JAK-1 inhibitors
As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; m...
Guardat en:
| Publicat a: | Rheumatology (Oxford) |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8098103/ https://ncbi.nlm.nih.gov/pubmed/33950230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keaa895 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|